FDA clears laser therapy for vitiligo:
This article was originally published in Clinica
The US FDA has cleared for sale what it claimed is the first excimer laser system for treating vitiligo, a skin disease that causes a loss of pigmentation. The XTRAC laser device, made by Photomedex of Radnor, Pennsylvania, eradicates the white spots caused by vitiligo, restoring the skin to the same condition as before the onset of the disease. The company says that until now, there has been no known cure or effective treatment for the disease, which is known to affect around two to four million people in the US.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.